MX2009004670A - Compuestos para inhibir la progresion mitotica. - Google Patents

Compuestos para inhibir la progresion mitotica.

Info

Publication number
MX2009004670A
MX2009004670A MX2009004670A MX2009004670A MX2009004670A MX 2009004670 A MX2009004670 A MX 2009004670A MX 2009004670 A MX2009004670 A MX 2009004670A MX 2009004670 A MX2009004670 A MX 2009004670A MX 2009004670 A MX2009004670 A MX 2009004670A
Authority
MX
Mexico
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
cancer
Prior art date
Application number
MX2009004670A
Other languages
English (en)
Spanish (es)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009004670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX2009004670A publication Critical patent/MX2009004670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2009004670A 2006-11-16 2007-11-14 Compuestos para inhibir la progresion mitotica. MX2009004670A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
MX2009004670A true MX2009004670A (es) 2009-05-15

Family

ID=39315133

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012011396A MX348568B (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresión mitótica.
MX2012011398A MX343391B (es) 2006-11-16 2007-11-14 Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina.
MX2009004670A MX2009004670A (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresion mitotica.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012011396A MX348568B (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresión mitótica.
MX2012011398A MX343391B (es) 2006-11-16 2007-11-14 Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina.

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2086981B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101110458B1 (enExample)
CN (2) CN103483343B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2497772T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2384123T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX348568B (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ611898A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2086981T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS53788B1 (enExample)
SG (2) SG176443A1 (enExample)
SI (2) SI2497772T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN104031049A (zh) * 2010-02-19 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂的结晶形式
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP5844358B2 (ja) * 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイＩｃａｈｎ Ｓｃｈｏｏｌ ｏｆ Ｍｅｄｉｃｉｎｅ ａｔ Ｍｔ． Ｓｉｎａｉ 抗がん剤としての複素環式の限定された三環系スルホンアミド
CN108349943A (zh) 2015-09-09 2018-07-31 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
US11340215B2 (en) 2016-02-26 2022-05-24 Japanese Foundation For Cancer Research Screening method of anticancer agent focused on function of HP1 and evaluation system
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
CN119546309A (zh) 2022-04-08 2025-02-28 伊莱利利公司 包括kras g12c抑制剂和aurora a抑制剂的治疗方法
KR20250027777A (ko) 2022-06-30 2025-02-27 일라이 릴리 앤드 캄파니 암을 치료하기 위한 kras g12c 억제제
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CN1312135C (zh) 1997-09-29 2007-04-25 明治制果株式会社 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1236712B1 (en) 1999-12-06 2008-08-06 Ajinomoto Co., Inc. Amidinophenylpyruvic acid derivative
AP2003002825A0 (en) * 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EP1962830B1 (en) 2005-12-23 2013-03-27 GlaxoSmithKline LLC Azaindole inhibitors of aurora kinases
JP2010500352A (ja) 2006-08-09 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
JP5102839B2 (ja) 2012-12-19
IL198690A0 (en) 2010-02-17
PH12012502057B1 (en) 2018-10-24
MA30988B1 (fr) 2009-12-01
AU2007322046A1 (en) 2008-05-29
SI2086981T1 (sl) 2012-12-31
DK2497772T3 (en) 2015-01-19
CY1112828T1 (el) 2016-02-10
EP2944639B1 (en) 2017-01-04
SG10201503350TA (en) 2015-06-29
UA94129C2 (ru) 2011-04-11
PT2497772E (pt) 2015-02-05
CN103483343A (zh) 2014-01-01
EP2086981B1 (en) 2012-05-02
KR20090091173A (ko) 2009-08-26
JP5452811B2 (ja) 2014-03-26
HK1217699A1 (en) 2017-01-20
US9988384B2 (en) 2018-06-05
RS52313B (sr) 2012-12-31
CA2669680C (en) 2012-04-10
US20080167292A1 (en) 2008-07-10
US9765076B2 (en) 2017-09-19
CN103483343B (zh) 2016-06-01
CR20140154A (es) 2014-07-23
TW200829589A (en) 2008-07-16
NO20091864L (no) 2009-06-15
HRP20120490T1 (hr) 2012-07-31
JP2012006965A (ja) 2012-01-12
US8026246B2 (en) 2011-09-27
JP2014055166A (ja) 2014-03-27
ES2528793T3 (es) 2015-02-12
PL2497772T3 (pl) 2015-05-29
ATE556076T1 (de) 2012-05-15
EP2497773B1 (en) 2015-02-25
MY153243A (en) 2015-01-29
JP2010510215A (ja) 2010-04-02
EP2497772A1 (en) 2012-09-12
EP2086981A1 (en) 2009-08-12
SG176443A1 (en) 2011-12-29
PT2086981E (pt) 2012-06-20
GEP20125459B (en) 2012-03-26
ES2384123T3 (es) 2012-06-29
US20150166545A1 (en) 2015-06-18
AU2007322046B2 (en) 2012-04-05
CN101547924B (zh) 2013-09-25
US20110312943A1 (en) 2011-12-22
ZA200903279B (en) 2010-07-28
US20240400567A1 (en) 2024-12-05
KR20110113210A (ko) 2011-10-14
DK2086981T3 (da) 2012-08-06
CR20140544A (es) 2015-01-12
US20110312942A1 (en) 2011-12-22
HK1134672A1 (en) 2010-05-07
EA200970486A1 (ru) 2009-10-30
US20190031662A1 (en) 2019-01-31
PL2086981T3 (pl) 2012-09-28
PH12012502057A1 (en) 2015-09-14
US20210214361A1 (en) 2021-07-15
BRPI0718803B8 (pt) 2021-05-25
US11958855B2 (en) 2024-04-16
BRPI0718803A2 (pt) 2013-12-03
SI2497772T1 (sl) 2015-03-31
HK1175778A1 (en) 2013-07-12
EA015779B1 (ru) 2011-12-30
MX343391B (es) 2016-11-04
US10836766B2 (en) 2020-11-17
CL2007003244A1 (es) 2008-04-04
MX348568B (es) 2017-06-20
EP2497772B1 (en) 2014-10-29
ES2537451T3 (es) 2015-06-08
AR064246A1 (es) 2009-03-25
CR10782A (es) 2009-06-24
HK1175777A1 (en) 2013-07-12
NZ577042A (en) 2012-03-30
BRPI0718803B1 (pt) 2020-11-17
NZ597252A (en) 2013-06-28
TWI401255B (zh) 2013-07-11
WO2008063525A1 (en) 2008-05-29
CA2669680A1 (en) 2008-05-29
NO343338B1 (no) 2019-02-04
EP2497773A1 (en) 2012-09-12
NZ611898A (en) 2015-01-30
RS53788B1 (sr) 2015-06-30
CN101547924A (zh) 2009-09-30
HRP20150047T1 (en) 2015-03-13
KR101110458B1 (ko) 2012-03-13
EP2944639A1 (en) 2015-11-18
KR101342014B1 (ko) 2013-12-19

Similar Documents

Publication Publication Date Title
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
MY148634A (en) Pyridazinone derivatives
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
WO2009155121A3 (en) Inhibitors of pi3 kinase
SG179418A1 (en) Inhibitors of the hedgehog pathway
TW200800963A (en) Chemical compounds
SI1853602T1 (sl) Kemične spojine
PL1853588T3 (pl) Związki chemiczne
NZ577916A (en) Cyclopamine analogs
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21
IL191670A0 (en) Compounds for the inhibition of apoptosis
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MY159181A (en) Use of an anti-cancer compound
EP1905773A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Legal Events

Date Code Title Description
FG Grant or registration